The Global Next Generation Cancer Diagnostics Market accounted for US$ 5650.9 Million 2020 and is estimated to be US$ 28,746.19 million by 2030 and is anticipated to register a CAGR of 19.8%. NGS is arguably one of the most significant technological advances in biology in the last 30 years. Medical research has embraced technology because of the genetic nature of cancer, and the cancer sector is at the forefront of these efforts. New discoveries are likely to lead to new diagnostic, prognostic, and therapeutic targets as a result of global efforts to catalogue mutations in a range of cancer forms. NGS has advanced to the point where it is being considered for routine diagnostic use by some laboratories. In the research community, NGS has been widely employed for de novo genome sequencing, DNA resequencing, transcriptome sequencing, and epigenomics. These researches have led the way for the creation of new processes (both molecular and bioinformatic), as well as a deeper understanding of the technology's main advantages and disadvantages.
The report "Global Next Generation Cancer Diagnostics Market, By Technology (RT-PCR, Next Generation Sequencing, DNA Microarray, Lab-on–a-chip and Others), By Cancer Type (Lung cancer, Prostate cancer, Breast cancer, Colorectal cancer and Others), By Application (CTC Analysis, Biomarker, Proteomic Analysis and Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030”
Key Highlights:
· In July 2021, Labcorp (NYSE: LH), a leading global life sciences company, announced the availability of therascreen KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS™ (sotorasib), a new treatment option developed by Amgen.
· In July 2021, Labcorp (NYSE: LH), a leading global life sciences company, and OmniSeq, a CAP-accredited, molecular diagnostic innovation of Roswell Park Comprehensive Cancer Center, announced the launch of OmniSeq INSIGHT, a comprehensive genomic and immune profiling, tissue-based test that integrates next-generation sequencing (NGS) technology. The test is designed to advance precision oncology and improve patient outcomes, as part of Labcorp's commitment to empower better health decisions for patients through the addition of cutting-edge diagnostic tools in precision medicine.
Analyst View:
As the incidence of oncology problems develops, demand for next-generation cancer diagnostic tools is likely to rise. These tests are expected to aid in the early identification and accurate prognosis of a variety of cancers, positively impacting the vertical's growth over the projection period. The development and introduction of product offerings by a number of significant firms is expected to provide attractive growth opportunities for this industry. Many hospitals in impoverished countries are unable to invest in diagnostic imaging technology due to rising prices, decreasing reimbursement rates, and fiscal constraints. However, due to the rising demand for diagnostic imaging services in these nations, hospitals that cannot afford to buy new imaging equipment opt for used systems.
To know the upcoming trends and insights prevalent in this market, click the link below:
Key Market Insights from the report:
The Global Next Generation Cancer Diagnostics Market accounted for US$ 5650.9 Million 2020 and is estimated to be US$ 28,746.19 million by 2030 and is anticipated to register a CAGR of 19.8%. The Global Next Generation Cancer Diagnostics Market is segmented based on the technology, cancer type, application and region.
· By Technology, the Global Next Generation Cancer Diagnostics Market is segmented into RT-PCR, Next Generation Sequencing, DNA Microarray, Lab-on–a-chip and Others.
· By Cancer Type, the market is segmented in Lung cancer, Prostate cancer, Breast cancer, Colorectal cancer and Others.
· By Application, the Global Next Generation Cancer Diagnostics Market is segmented into CTC Analysis, Biomarker, Proteomic Analysis and Others.
· By Region, the Global Next Generation Cancer Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the Next Generation Cancer Diagnostics market.
Relative Report:
https://prophecymarketinsights.blogspot.com/2022/03/global-enteral-feeding-devices-market.html
To know more
Contact Us:
Sales
Prophecy Market Insights
Email- [email protected]
Global next generation cancer diagnostics market size was worth USD 4,964.05 million in 2016 which is anticipated to grow at a CAGR of more than 9.7% over the forecast period.
The introduction of new products by large bodies, merger, and acquisitions, and joint agreements such as the development of RNA-Seq Kit version by Agilent Technologies Inc. and Agendia Inc. are the factors accountable for the estimated CAGR.An escalation in the development of companion diagnostics in order to deliver advanced and personalized genomic medicine is also responsible for progress in the coming years.Furthermore, the technological advancements driving the innovation in point-of-care testing devices is anticipated to aid in commercialization of advanced products thereby supporting revenue generation.Download Sample Report @ https://www.millioninsights.com/industry-reports/next-generation-cancer-diagnostics-market/request-sampleIncorporation of technological advancements such as melting curve examination for identification of mutations, qPCR tools for profiling of tumor in clinical test centers, and gene deletions are accountable for the largest share apprehended by multiplexing and qPCR segment.With the development of next-generation sequencing technology, the use of traditional methods such as protein and DNA microarrays is expected to decrease through the years.
Other factors such as data interpretation tools, growth of supportive library preparation procedures, and technological advancements are accountable for the lucrative adoption of next generation oncology tests among researchers.Cancer Type InsightsMajor categorization for the types of cancer includes cervical, breast, lung, colorectal, and other tumor forms.
The other types constitute leukemia, prostate, bladder, brain, skin, uterine, esophageal, Non-Hodgkin lymphoma, ovarian, liver, and thyroid.In 2015, as per World Health Organization lung cancer was accountable for approximately 1.7 million deaths.
Moreover, breast cancer incidence is also estimated to grow thereby escalating the demand for screening and diagnostic technologies.Application InsightsGrowth in the number of research schemes to develop novel products and services which enable primary detection of tumor-causing mutations is expected to affect the advancement in genetic analysis over the forecast period.
Biomarker tests offer greater sensitivity in screening and also demonstrate 90% accuracy levels in investigational studies which is attributive to induce progress in the coming years.Function InsightsRisk analysis, prognostic based diagnosis, tumor screening, therapeutic monitoring, & theranostics are the different functions of next generation oncology diagnostic tests.The prognostic diagnostics segment is anticipated to witness the fastest growth in the coming years as a consequence of higher adoption of prognosis which plays important role in designing oncology therapies and protocols for chemotherapy, radiation-based treatment, and gene therapy.Regional InsightsThe next generation cancer diagnostics market is dominated by North America with approximately 40% market share.
Next Generation Cancer Diagnostics Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.Get FREE Sample Report Before Buying @ https://www.upmarketresearch.com/home/requested_sample/8213UpMarketResearch offers a latest published report on “Global Next Generation Cancer Diagnostics Market Analysis and Forecast 2018-2023” delivering key insights and providing a competitive advantage to clients through a detailed report.
The report contains 109 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.Next Generation Cancer Diagnostics Industry research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.
Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, PESTLE analysis and so on.
The statistics are represented in graphical format for a clear understanding on facts and figures.The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders.
Secondary research techniques are implemented for better understanding and clarity for data analysis.The report for Next Generation Cancer Diagnostics market analysis & forecast 2018-2023 is segmented into Product Segment, Application Segment & Major players.Region-wise Analysis Global Next Generation Cancer Diagnostics Market covers:North AmericaEuropeChinaJapanIndiaSoutheast AsiaOther regions (Central & South America, Middle East & Africa)The Major players reported in the market include:CepheidKoninklijke Philips N.VHoffmann-La Roche LtdQiagenNovartis AGAbbottThermo Fisher ScientificOpko HealthMyriad GeneticsAgilent TechnologiesGE HealthcarePerkinElmerGenomic HealthIlluminaHologicAlmac GroupJanssen Global ServicesSysmex CorporationFor More Information, Please Visit https://www.upmarketresearch.com/home/enquiry_before_buying/8213Global Next Generation Cancer Diagnostics Market: Product Segment Analysis:Next Generation SequencingqPCR & MultiplexingDNA MicroarraysOtherGlobal Next Generation Cancer Diagnostics Market: Application Segment Analysis:HospitalsClinicsOtherThe Report covers in-depth analysis as follows:Chapter 1 Report OverviewChapter 2 Global Growth TrendsChapter 3 Market Share by Key PlayersChapter 4 Breakdown Data by Type and ApplicationChapter 5 United StatesChapter 6 EuropeChapter 7 ChinaChapter 8 JapanChapter 9 Southeast AsiaChapter 10 IndiaChapter 11 Central & South AmericaChapter 12 International Players ProfilesChapter 13 Market Forecast 2018-2025Chapter 14 Analyst's Viewpoints/ConclusionsChapter 15 AppendixBuy Next Generation Cancer Diagnostics Market analysis & forecast 2018-2023 Report along with complete TOC @ https://www.upmarketresearch.com/buy/next-generation-cancer-diagnostics-market“Next Generation Cancer Diagnostics Market Analysis and Forecast 2018-2023” report helps the clients to take business decisions and to understand strategies of major players in the industry.
Next Generation Cancer Diagnostics market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025.
This report focuses on the global Next Generation Cancer Diagnostics status, future forecast, growth opportunity, key market and key players.
The study objectives are to present the Next Generation Cancer Diagnostics development in United States, Europe and China.
The key players covered in this studyCepheidKoninklijke Philips N.VF.
Hoffmann-La Roche LtdQiagenNovartis AGAbbottThermo Fisher ScientificOpko HealthMyriad GeneticsAgilent TechnologiesGE HealthcarePerkinElmerGenomic HealthIlluminaHologicAlmac GroupJanssen Global ServicesSysmex CorporationMarket segment by Type, the product can be split into Next Generation SequencingqPCR & MultiplexingDNA MicroarraysOtherReport Sample includes:- Table of Contents- List of Tables & Figures- Charts- Research MethodologyGet FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-next-generation-cancer-diagnostics-2019-2025-401/?utm_source=techsite_Nikhil Agrawal_medium=ReferralMarket segment by Application, split into HospitalsClinicsOtherMarket segment by Regions/Countries, this report covers United StatesEuropeChinaJapanSoutheast AsiaIndiaCentral & South AmericaThe study objectives of this report are: To analyze global Next Generation Cancer Diagnostics status, future forecast, growth opportunity, key market and key players.To present the Next Generation Cancer Diagnostics development in United States, Europe and China.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by product type, market and key regions.In this study, the years considered to estimate the market size of Next Generation Cancer Diagnostics are as follows: History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025Get the Complete Report & TOC at https://www.24marketreports.com/life-sciences/global-next-generation-cancer-diagnostics-2019-2025-401/?utm_source=techsite_Nikhil Agrawal_medium=ReferralCONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170Email: [email protected] Us On linkedin :- https://www.linkedin.com/company/24-market-reports
